A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2001
11/22/2001	WO2001087324A1 Compositions and methods for promoting immunosuppression
11/22/2001	WO2001087323A2 Method for treating cartilage disorders
11/22/2001	WO2001087322A2 Peptide pharmaceutical formulations
11/22/2001	WO2001087321A2 Glycosyltransferase proteins
11/22/2001	WO2001087315A1 Treatment or prevention of metabolic bone disorder
11/22/2001	WO2001087314A1 Methods and compositions for promoting angiogenesis using monocytes
11/22/2001	WO2001087312A1 Polyethylene glycol (peg) polymers for the promotion of angiogenesis
11/22/2001	WO2001087286A2 Antisense enzyme inhibitors for improving pharmacokinetics of a drug
11/22/2001	WO2001087285A2 Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors
11/22/2001	WO2001087284A2 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	WO2001087278A1 Insulin formulation for inhalation
11/22/2001	WO2001087270A2 Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
11/22/2001	WO2001087268A1 Micellar pharmaceutical compositions for buccal and pulmonary application
11/22/2001	WO2001087265A2 Pharmaceutical form of administration for peptides, methods for its production and use
11/22/2001	WO2001087263A2 Delivery systems for treatment of vascular disease
11/22/2001	WO2001087239A2 Methods of affecting laminin 5 processing
11/22/2001	WO2001087238A2 Induction of apoptosis and cell growth inhibition by protein 4.33
11/22/2001	WO2001087066A1 Vaccines, immunotherapeutics and methods for using the same
11/22/2001	WO2001087039A2 Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
11/22/2001	WO2001055333A8 Methods and materials relating to transforming growth factor alpha-like polypeptides and polynucleotides
11/22/2001	WO2001042246A3 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
11/22/2001	WO2001041534A3 Pseudomycin phosphate prodrugs
11/22/2001	WO2001038355A3 Method of forming a peptide-receptor complex with zsig33 and therapeutic use thereof
11/22/2001	WO2001036977A3 Identification of disease markers involving mass-based-separation
11/22/2001	WO2001036611A8 Process for the production of a reversibly inactive acidified plasmin composition
11/22/2001	WO2001036588A3 Fusion proteins that specifically inhibit protein synthesis in neuronal cells
11/22/2001	WO2001036476A3 Ing2, an iaps associated cell cycle protein, compositions and methods of use
11/22/2001	WO2001036465A3 Human zven proteins
11/22/2001	WO2001036462A3 Protein c derivatives
11/22/2001	WO2001034792A3 Compositions and methods for the diminution or elimination of various cancers
11/22/2001	WO2001034779A3 Human proteins with homology to carboxypeptidases and polynucleotides encoding the same
11/22/2001	WO2001032891A3 Human lipase
11/22/2001	WO2001032691A8 Hcv ns3 protease inhibitors
11/22/2001	WO2001031036A3 Modified viral surface proteins which bind to cells of tumor vasculature
11/22/2001	WO2001030986A3 Human pif1 dna helicase and uses thereof
11/22/2001	WO2001030969A8 Stanniocalcin proteins and nucleic acids and methods based thereon
11/22/2001	WO2001030371A3 Novel chimeric analgesic peptides
11/22/2001	WO2001028578A3 A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
11/22/2001	WO2001027269A3 Vip54 protein and related materials
11/22/2001	WO2001027268A3 Cell-permeable peptide inhibitors of the jnk signal transduction pathway
11/22/2001	WO2001026674A3 Method for treating otic disorders
11/22/2001	WO2001021795A3 Fatty acid transport proteins
11/22/2001	WO2001021631A3 Secreted proteins and uses thereof
11/22/2001	WO2001019993A3 Virulence genes of m. marinum and m. tuberculosis
11/22/2001	WO2001019385A3 The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses
11/22/2001	WO2001019380A3 Oncolytic virus
11/22/2001	WO2001018169A3 Agents and compositions and methods for diagnostic and/or treating or preventing plaque forming diseases
11/22/2001	WO2001015679A3 Mesoprogestins for the treatment and prevention of benign hormone dependent gynecological disorders
11/22/2001	WO2001014564A3 Polynucleotides expressed in activated t-lymphocytes and proteins encoded thereby
11/22/2001	WO2001011063A3 Gene transfer combination vectors, method for the production and utilization thereof
11/22/2001	WO2001000242A3 Polycation-based bioconjugates
11/22/2001	WO2000059542A9 Method for a programmed controlled ovarian stimulation protocol
11/22/2001	WO2000055633A9 Methods of screening for colorectal cancer modulators
11/22/2001	WO2000041710A9 Glycopeptide antibiotics containing a desmethylvancosamine residue, combinatorial libraries of same and methods of producing same
11/22/2001	WO2000010600A9 Activation and protection of t-cells (cd4+ and cd8+) using an h¿2? receptor agonist and other t-cell activating agents
11/22/2001	US20010044616 Surgical irrigation solution and method for inhibition of pain and inflammation
11/22/2001	US20010044528 5'-O-alkyl nucleotide, block of phosphodiester-linked 2'-O-alkyl ribonucleotides, a block of phosphorothioate-linked deoxyribonucleotides, and a blocking group for nuclease resistance; lipid-peptoid carrier
11/22/2001	US20010044523 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
11/22/2001	US20010044522 Polypeptides, antibodies against them and nucleic acids encoding them; detecting activated CD4+ T-cells to diagnose a disease or condition of the immune system; screening for immunosuppressants
11/22/2001	US20010044521 Especially those present in inclusion bodies in bacterial hosts, by maintaining alkaline pH in presence of chaotrophic or reducing agents, and decreasing pH gradually over given time to induce renaturation; proteomics
11/22/2001	US20010044465 Use of L-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
11/22/2001	US20010044459 Hydroxamic acid derivatives
11/22/2001	US20010044455 Method of treatment for decreasing mortality resulting from congestive heat failure
11/22/2001	US20010044453 Combination drug therapy for glycolipid storage diseases
11/22/2001	US20010044420 Treatment of mammalian cancer
11/22/2001	US20010044418 Treatment of allergies
11/22/2001	US20010044415 Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors
11/22/2001	US20010044145 Reduction of genetic expression of RNA target via antisense oligonucleotide
11/22/2001	US20010044120 Useful for the prevention or treatment of peptic ulcers in humans or mammals.
11/22/2001	US20010044110 Inhibition of mal1
11/22/2001	US20010043935 Use of polyamino acid derivatives to treat seborrhoea and the associated skin disorders
11/22/2001	US20010043934 Formulations for amylin agonist peptides
11/22/2001	US20010043930 Method for treating cervical dystonia with botulinum toxin type B
11/22/2001	US20010043928 Serum preparations for inhibiting retroviruses and tumor growth
11/22/2001	US20010043922 Recombinants of the multiply deficient adenoviral vectors; a therapeutic method and their use particularly relating to gene therapy and vaccination
11/22/2001	US20010043920 Delivering a dosage of a growth factor-encoding transgene composition to preselected delivery sites in the brain where the encoded growth factor is expressed and stimulates axonal growth; mimimally invasive; Alzheimer's, Parkinson diseases
11/22/2001	US20010043915 Method for administering a cytokine to the central nervous system and the lymphatic system
11/22/2001	US20010043914 In situ vaccination by administering to a tumor a slow-release microparticle containing Interferon-12; antigrowth, -tumor, -carcinogenic and -metastasis agents; with or without a synergistic cytokine
11/22/2001	US20010043906 Aerosolizing a solution of aqueous gamma-interferon, a stabilizer and a dispersant by forcing the solution through openings in a plate and delivering the droplets to a patient's respiratory tract; storage stability
11/22/2001	DE10024746A1 Feed additive comprising stress protein, chelate compound, phyto-mineral and nucleotide, useful for improving condition of immune system, organs and/or lipid metabolism in farm or domestic animals
11/22/2001	DE10023665A1 New human virus-inhibiting peptide, useful e.g. for treating viral or other infections or cancer, comprises fragment of alpha1-antitrypsin
11/22/2001	DE10018221A1 Treating disorders of the teeth, gums or jawbones using growth hormones, preferably human growth hormone or dehydroepiandrosterone, useful e.g. for treating paradontosis or healing jaw operation wounds
11/22/2001	DE10009119A1 Vertebraten Globin Vertebrate globin
11/22/2001	CA2411369A1 Antithrombotic agents
11/22/2001	CA2410056A1 Induction of apoptosis and cell growth inhibition by protein 4.33
11/22/2001	CA2410028A1 Ligands specific for an isoform of the prion protein
11/22/2001	CA2409746A1 Immunotoxin fusion proteins and means for expression thereof
11/22/2001	CA2409506A1 Method for cell adhesion and wound healing
11/22/2001	CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001	CA2409437A1 Aldosterone antagonist composition for release during aldosterone acrophase
11/22/2001	CA2409414A1 Ssa-56kda polypeptide and its fragments and polynucleotides encoding said polypeptides and therapeutic uses
11/22/2001	CA2409164A1 Novel nucleic acids and polypeptides
11/22/2001	CA2409154A1 Compositions, kits, and methods for identification and modulation of t helper-1 and t helper-2 cells and diseases associated therewith
11/22/2001	CA2409148A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
11/22/2001	CA2409108A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
11/22/2001	CA2409068A1 Novel dual oxidases as mitogenic and endocrine regulators
11/22/2001	CA2408974A1 Cancer treatments by using a combination of an antibody against her2 and interleukin -2
11/22/2001	CA2408827A1 Novel human lipocalin homologs and polynucleotides encoding the same
11/22/2001	CA2408745A1 Anti-angiogenic polypeptides
11/22/2001	CA2408729A1 Delivery systems for treatment of vascular disease

1 ... 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 ... 3163